Browse Articles

Discover research articles across all indexed journals

Impact of COVID-19 pandemic on critically ill patients with colon cancer: A population-level study.

Journal of Clinical Oncology Jorge Rodriguez Vazquez, Ahmed Bashir Sukhera, Gloria Erazo et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.297

297 Background: The COVID-19 pandemic strained healthcare systems and disrupted pre-pandemic levels and trends in the short-term mortality of colon cancer hospitalizations. Colon cancer is the fourth most diagnosed cancer in the US and Texas. The impact on short term mortality in Texas in the years since the COVID-19 pandemic have not been explored. Methods: We used publicly available, deidentified, and state-wide data to conduct a population-base cohort study of hospitalizations aged ≥ 18 years admitted to intensive care units at acute care hospitals in Texas during 2016-2022 with a diagnosis of colon cancer. Hospitalizations transferred to another acute care hospital were excluded from the study. Colon cancer was identified using ICD-10-CM codes C18x and C20 selected from Clinical Classification Software Refined category NEO015: Gastrointestinal cancers - colorectal. Short-term mortality was defined as in-hospital mortality or discharge to a hospice. The response variables are pre-pandemic time trend, level change, change in time trend, and final time trend. The primary analysis method was interrupted time series analysis (ITSA) based on multilevel-multivariable logistic regression with results reported as average marginal effects per quarter (AME) and 95% confidence intervals (95% CI) in changes to the absolute probability of mortality. The matched pairs t-test was applied to ITSA and counterfactual predicted probabilities to further elucidate the impact of the COVID-19 pandemic. Sensitivity analyses was performed for hospitalizations aged ≥ 65 years and for hospitalizations without a diagnosis of COVID-19. Results: A total of 49,007 hospitalizations were included in the study of which 21,995 (44.9%) occurred after the beginning of the pandemic. Unadjusted short-term mortality was lower in the pre-pandemic period compared to the post-pandemic period (18.1% vs 20.1%). On adjusted analysis, the post-pandemic period remained associated with higher mortality rates. The pre-pandemic short-term mortality time trend was negative (AME -0.19%/quarter, 95% CI [-0.28% to -0.10%], p = 0.0001). The change in time trend was positive (AME 0.39%/quarter, 95% CI [0.23% to 0.55%], p < 0.0001) and the change in level was also positive (AME 1.25%, 95% CI [0.0.04% to 2.47%], p = 0.0436). The final time trend was significant and positive (AME 0.20%/quarter, 95% CI [0.07% to 0.33%], p = 0.0023). The point estimate and 95% CI for the difference between ITSA predicted and counterfactual predicted probabilities of mortality was 3.45% (3.41% to 3.48%). Similar results were observed on sensitivity analyses. Conclusions: Since the onset of the pandemic there was a 2% increase in the absolute probability of short-term mortality and a change from negative to positive time trend in short-term mortality. The average impact of the COVID-19 pandemic on the absolute probability of short-term mortality is estimated at over 3%.

Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial.

Journal of Clinical Oncology Bo Feng, Jingyi Liu, Tao Ma et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.133

133 Background: Total neoadjuvant therapy (TNT) intensified by the combination of targeted therapy or immunotherapy is warranted to achieve satisfying local and systemic control for high-risk locally advanced rectal cancer (LARC). Our study aimed to explore the efficacy and safety of a FOLFOX-based TNT regimen plus bevacizumab and short-course radiotherapy (SCRT) in Ras-mutant high-risk LARC patients. Methods: In this single-arm, single-center, phase II trial, LARC patients with at least one risk factor (cT3c-4, mesorectal fascia positive, cN2, lateral lymph node involvement, and extramural venous invasion positive) were recruited and only Ras-mutant patients were included. Four cycles of FOLFOX plus bevacizumab were arranged as induction chemotherapy followed by SCRT (25Gy/5Fx) and two cycles of FOLFOX as consolidation chemotherapy. Surgery was performed 8 weeks after completion of radiotherapy. After surgery, high-risk stage III patients (T4 or N2) were recommended to receive an extra 6 cycles of FOLFOX as adjuvant chemotherapy, while low-risk stage III patients were scheduled for regular follow-up. Patients with clinical complete response(cCR) were allowed to choose the “Watch & Wait” (W&W) strategy instead of surgery. The primary endpoint was the complete response (CR) rate, defined as the total rate of cCR plus pathological complete response (pCR). Secondary endpoints included adverse events of TNT, postoperative complications, 2-year disease-free survival, and overall survival. Results: Between April 2, 2021, and March 12, 2024, 47 of 51 enrolled patients were eligible for treatment. All patients completed the prescribed TNT cycles, and six (12.8%) of them had dose reduction. The CR was achieved in 18 (38.3%) patients, including 14 (29.8%) pCR. No grade IV-V toxicity was observed and the incidence of grade III toxicities was 34.0%. Four patients (8.5%) achieved cCR and chose the W&W strategy. The other 43 patients underwent curative surgery and anal preservation was achieved in 39 (90.7%) patients. Seven patients (16.3%) experienced postoperative complications, including four (9.3%) cases of anastomotic leakage. Conclusions: The intensified TNT regimen combined with bevacizumab achieved a satisfying CR rate with acceptable toxicities and complications for Ras-mutant high-risk LARC patients. Long-term survival data of this cohort are needed to validate the efficacy of this regimen further. Clinical trial information: NCT04923620 .

Clinical outcomes of hypofractionated radiotherapy (5x5 Gy) with a simultaneous integrated boost (5x6 Gy) in locally advanced rectal cancer.

Journal of Clinical Oncology Maciej Temnyk, Katarzyna Pędziwiatr, Małgorzata Gidzińska-Wielgosz et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.60

60 Background: Hypofractionated RT (5x5 Gy) with or without subsequent chemotherapy is a standard of care used at the National Institute of Oncology, Warsaw, Poland, as a preoperative treatment for locally advanced rectal cancer. To maximize the chance of achieving a complete response (CR), when surgery is not planned or when there are clinically involved lymph nodes located outside the standard TME field, RT can be augmented with a simultaneous integrated boost (SIB) delivering 5x6 Gy. This report aims to evaluate the clinical outcomes of hypofractionated RT with a SIB in rectal cancer. Methods: From Dec 2018 to Sep 2022, 78 consecutive pts with a median age of 67 years (range 36–89 years), received hypofractionated RT utilizing the SIB-VMAT technique. The radiation dose fractionation was 5x5 Gy to the rectum, mesorectum and elective lymph nodes and a SIB to the GTV for a total dose of 30 Gy. Results: 30 pts (38.5%) received a SIB for the rectal tumor, of which 15 pts (19.2%) were deemed unfit for surgery, 10 pts (12.8%) refused surgical treatment, 3 pts (3.8%) had an oligometastatic disease, and 2 pts (2.6%) had an advanced primary tumor. 48 pts (61.5%) received a SIB to the clinically involved lymph nodes located outside the standard TME field. All 78 pts completed RT as planned without interruptions or dose modifications and with an acceptable toxicity profile. There was a 26.9% (n = 21) incidence of G2 toxicities (diarrhea, proctitis, skin toxicity, cystitis or lumbosacral plexus neuropathy) and a 3.8% (n = 3) incidence of G3 toxicities (diarrhea or proctitis). After a median follow-up of 917 days (range 33–1927 days), an assessment of response was conducted in 68 cases. In 94.1% (n = 64) there was no progression at the site irradiated to a dose of 30 Gy. After completion of RT, mr-TRG was evaluated in 28 pts. In 46.4% (n = 13) mr-TRG 1-2 (cCR) was achieved. Of the 24 pts qualified for the watch and wait strategy, 17 had follow-up. Of this group, 64.7% (n = 11) remained progression-free, and 11 pts had an adequate evaluation for cCR (imaging and endoscopy), resulting in a 63.6% (n = 7) rate of cCR. 43 pts underwent surgery, of which 97.7% (n = 42) had R0 resection. In 41 cases pathological TRG was assessed according to AJCC or Ryan, of which 41.4% (n = 17) achieved TRG 0-1 (pCR). In 40 cases the operated pts had no initial metastatic spread, among them 67.5% (n = 27) remain disease-free. 67 pts reported disease-related symptoms before RT. After treatment, 89.6% (n = 60) of those pts achieved symptomatic improvement in either rectal bleeding, bowel frequency, or pain control. Conclusions: Hypofractionated RT with SIB-VMAT delivering a dose of 30 Gy/25 Gy/5 fractions provides good local control and is a safe and viable option for both young and elderly patients who will not undergo surgery and for patients with involved lymph nodes located outside the standard TME field to maximize the chance of achieving CR.

Application of chokeberry biochar as a modified additive to the vegetable lubricants: the tribological and rheological properties

Scientific Reports Rafal Kozdrach, Pawel Radulski Feb 01, 2025 DOI: 10.1038/s41598-025-87374-0

Cost-effectiveness of blood-based colorectal cancer screening: A simulation model incorporating real-world longitudinal adherence.

Journal of Clinical Oncology Elifnur Yay Donderici, Shaun P. Forbes, Nicole Zhang et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.93

93 Background: Colorectal cancer (CRC) is a predominant cause of cancer-related mortality worldwide. Regular screening improves outcomes. However, despite there being many U.S. Preventive Services Task Force (USPSTF) recommended CRC screening options, many people elect not to use any of them. Most cost-effectiveness models assume perfect (100%) adherence initially and over time (longitudinally), which is implausible as approximately one-third of eligible individuals are not up to date with CRC screening. Our study evaluates the cost-effectiveness of Shield, an FDA-approved blood-based CRC test, while incorporating real-world adherence. Methods: The CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model is a validated, discrete-event simulation model designed to evaluate the clinical and economic outcomes of CRC screening strategies under real-world adherence scenarios. We simulated individual lifetime outcomes for a cohort of 10,000 people beginning screening at age 45, running 4,000 trials per cohort. We conducted a cost-effectiveness analysis using the CAN-SCREEN model, and compared the Shield blood-based test administered every three years to no screening. Costs were calculated from a healthcare perspective and adjusted to 2023 US dollars. Shield was considered cost-effective if the incremental cost-effectiveness ratio (ICER) was below $100,000 per quality-adjusted life-year (QALY) gained. The analysis also assessed the maximum price Shield could maintain while remaining cost-effective. Results: Compared to no screening, Shield increased the number of QALYs by 154 per 1,000 individuals and raised costs by $7.5 million per 1,000 individuals at its commercial test cost. With an incremental cost of $48,662 per QALY gained, Shield was found to be cost-effective relative to no screening at $100,000 cost per QALY willingness-to-pay threshold. Furthermore, the unit cost of Shield can be as high as $3,241 and $4,942 to be considered cost-effective at $100,000 and $150,000 per QALY gained, respectively. Conclusions: This study used the CAN-SCREEN model to compare Shield, an FDA-approved blood-based CRC screening test, against no screening, finding that Shield is cost-effective. With about one-third of the U.S. population not up to date on CRC screening, Shield's noninvasive approach offers a promising, cost-effective solution to increase adherence and reduce CRC mortality. Economic outcomes of Shield against no screening using CAN-SCREEN model. Intervention Test Unit Cost QALYs/Person Cost ($)/Person Cost ($)/QALY Gained vs No screening No Intervention - 15.269 $6,312.18 - Shield $1,495 15.423 $13,786.72 $48,662 Shield $3,241 15.423 $21,672.34 $100,000.00 Shield $4,942 15.423 $29,352.42 $150,000.00

Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.

Journal of Clinical Oncology Keitaro Shimozaki, Koshiro Fukuda, Akira Ooki et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.341

341 Background: Based on the results of CheckMate-649 and ATTRACTION-4, nivolumab plus chemotherapy is the new standard of care as first-line treatment for patients with HER2-negative advanced gastric cancer (AGC) regardless of PD-L1 combined positive score (CPS) status in Japan. This study aimed to evaluate the safety and efficacy of this regimen in real-world patients with HER2-negative AGC with a longer follow-up. Methods: In this single-institutional retrospective study, patients with HER2-negative AGC who were treated with first-line nivolumab plus chemotherapy between September 2021 and April 2024 were consecutively enrolled and evaluated. Early tumor shrinkage (ETS) was defined as ≥20% tumor reduction at 8 ± 2 weeks. Results: Of 151 patients, median age was 66 years (range, 27–83); 58% were male; 81% had diffuse-type histology; the peritoneal metastasis was seen in 60%; PD-L1 CPS of <1, 1≤/<5, 5≤ was 30%/41%/29%; deficient mismatch repair and/or high microsatellite instability was 7%. At a median follow-up of 14.2 months, the median overall survival (OS) and progression-free survival (PFS) were 21.7 months (95% confidence interval [CI] 14.4–26.2) and 7.7 months (6.4–9.6), respectively. The median OS according to CPS subgroups (<1, 1≤/<5, 5≤) were 21.7 / not reached (NR) /25.0 months, respectively (log-rank P = 0.55). In patients with measurable lesions at baseline according to RECIST ver 1.1, the objective response rate and disease control rate were 62% and 87%, respectively, with a complete response rate of 10%. In the exploratory analysis by ETS, both median PFS and OS were significantly longer in the ETS group compared to the non-ETS group (PFS, NR vs. 6.2 months; hazard ratio [HR] 0.35; 95% CI 0.17–0.68; P = 0.001) (OS, 25.0 vs. 11.7 months; HR 0.44; 95% CI 0.20–0.93; P = 0.03). The immune-related adverse events (irAEs) of any grade were observed in 26% (grade 3–4 irAEs 12%), whereas no treatment-related death was documented. Conclusions: The updated analysis suggests that first-line nivolumab plus chemotherapy provides benefit in real-world patients with HER2-negative AGC regardless of PD-L1 status, and suggests that the magnitude of ETS may predict a significant impact on the duration of survival.

Comparative restricted mean survival time (RMST) analysis of survival in advanced hepatocellular carcinoma (aHCC) from pivotal phase III trials: IMbrave-150, ORIENT-32, CARES-310, HIMALAYA, and CM-9DW.

Journal of Clinical Oncology Roberto A. Pazo Cid, Carmen Blanco Abad, Paula Gomila Pons et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.597

597 Background: In advanced hepatocellular carcinoma (aHCC), the evaluation of overall survival (OS) and progression-free survival (PFS) through restricted mean survival time (RMST) provides a nuanced understanding of treatment efficacy. The RMST analysis serves as a valuable complement to the hazard ratio (HR) analysis, offering insights into the average survival time over a specified period. This study compares RMST analyses of OS at 24 and 36 months, and PFS at 12 and 18 months, across five pivotal phase III trials: IMbrave-150, ORIENT-32, CARES-310, HIMALAYA, and CM-9DW. Methods: Data from the experimental arms of the five phase III trials were analyzed. The RMST was calculated using the area under the Kaplan-Meier survival curves up to the specified time points. Specifically, OS was evaluated at 24 and 36 months, and PFS at 12 and 18 months. The RMST provides an estimate of the average time that patients survive (for OS) or remain progression-free (for PFS) within a specific timeframe. Kaplan-Meier survival curves were digitized if not available in raw form, and the area under the curve (AUC) was computed using numerical integration methods. RMST values were extracted from the AUC for the specified periods. This approach accounts for censored data and provides a robust comparison of survival times across different treatment groups. Results: The results for OS RMST at 24 and 36 months and PFS RMST at 12 and 18 months are summarized in the table. Conclusions: Angiogenesis inhibitor + immune checkpoint inhibitor combinations (Atezolizumab + Bevacizumab; Sintilimab + IBI305) provide the most favorable RMST outcomes in terms of OS and PFS. Restricted mean survival time (RMST) comparison of OS and PFS (months). aHCC 1L Phase III Trials Treatment Arm OS 24m OS 36m PFS 12m PFS 18m IMbrave-150 1, 2 Atezolizumab + Bevacizumab 17.50 22.79 9.69 13.29 ORIENT-32 3 Sinitilimab + IBI305 17.01 21.09 9.18 12.54 CARES-310 4 Camrelizumab + Rivoracenib 16.34 19.75 9.29 12.14 HIMALAYA 5, 6 Tremelimumab + Durvalumab 15.36 18.76 8.95 12.02 CM-9DW 7, 8 Nivolumab + Ipilimumab 15.87 20.08 8.74 11.78 1 Finn et al. N Engl J Med 2020;382:1894-905; 2 Cheng et al. J Hepatol 2022;76:862-873; 3 Ren et al. Lancet Oncol 2021;22:977–90; 4 Qin et al. Lancet 2023;402:1133–46; 5 Abou-Alfa et al. NEJM Evid 2022;1(8):EVIDoa2100070; 6 Sangro et al. Ann Oncol 2024;35:448-457; 7 Galle et al. J Clin Oncol 2024;42(suppl 17):abstr LBA4008; 8 Decaens et al. Ann Oncol 2024;35:S657.

Atractylenolide I prevents acute liver failure in mouse by regulating M1 macrophage polarization

Scientific Reports Hui Zhang, Min Gao, Haiyan Wang et al. Feb 01, 2025 DOI: 10.1038/s41598-025-86977-x

Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma.

Journal of Clinical Oncology Feng Shi, Zhenwei Peng, Dongdong Xia et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.580

580 Background: Lenvatinib stands out as a first-line therapy for individuals with advanced hepatocellular carcinoma (HCC). Concurrently, hepatic arterial infusion chemotherapy comprising oxaliplatin, fluorouracil, and leucovorin (FOLFOX-HAIC) has emerged as a potential option for those with advanced HCC. It is necessary to investigate the efficacy and safety of lenvatinib plus FOLFOX-HAIC (lenvaHAIC) for advanced HCC in real-world situations. Methods: In this retrospective analysis, 127 consecutive patients underwent lenvaHAIC, while 184 patients received lenvatinib alone as first-line treatment at six Chinese academic centers between January 2019 and June 2022. Following 1:1 propensity-score matching, we established paired cohorts (113 patients in each group) for evaluating survival. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) evaluated by RECIST 1.1 and mRECIST criteria, and safety profiles were compared between the two groups. Results: The lenvaHAIC group exhibited significantly prolonged median PFS and OS than the lenvatinib group (PFS: 12.3 vs. 6.2 months; OS: 25.6 vs. 12.3 months; P < .001 for each). In the propensity-score matched cohorts (113 pairs), both PFS and OS were notably extended in the lenvaHAIC group compared with those in the lenvatinib group (P < .001). Multivariate analysis identified lenvaHAIC treatment as an independent factor for improved PFS (hazard ratio [HR] 0.45; P < .001) and OS (HR 0.38; P < .001). Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group. Conclusions: LenvaHAIC may be a promising treatment in patients with advanced hepatocellular carcinoma, demonstrating enhanced OS, PFS, and ORR and an acceptable safety profile.

Positive homologous recombination signature (HRDsig+) and the genomic landscape of intrahepatic cholangiocarcinoma (iCCA).

Journal of Clinical Oncology Nakul Manish Shah, Dean Pavlick, Jeffrey S. Ross et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.627

627 Background: Defective DNA repair has not been a major focus in iCCA clinical research. In this comprehensive genomic profiling (CGP) study, we queried whether the presence of a scar-based HRDsig biomarker could identify a subset of patients with unique genomic alterations (GA) and potential for responsiveness to PARP inhibitor-based treatment regimens. Methods: 6,271 cases of clinically advanced iCCA underwent hybrid capture based CGP to evaluate all classes of GA. Microsatellite instability (MSI) status, tumor mutation burden (TMB) levels, genomic ancestry and genomic trinucleotide signatures were determined from the sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features (PMID 37769224). PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score (TPS). Results were compared using the Fisher exact system with the Benjamini-Hochberg procedure. Results: 288 (4.6%) of the sequenced iCCA featured an HRDsig+ status. Gender distribution (46-49% male) and median age (67 years) were similar in both HRDsig+ and HRDsig- iCCA. More pathogenic GA per tumor were found in HRDsig+ vs HRDsig- iCCA (5 vs 4; P<0.0001). Genomic ancestry distribution was similar; European ancestry ranged from 73% to 76% in the two cohorts. The APOBEC signature was uncommon but slightly more frequent in the HRDSig+ cases (1.7% vs 0.4%; P=.034). MSI High status was slightly more frequent in the HRDsig- group (1.8% vs 0.0%; P=0.034). Median TMB was higher in the HRDsig+ cases (3.6 vs 1.2 mut/Mb; P<0.0001) as was the frequency of TMB > 10 mut/Mb (9.1% vs 3.5%; P<0.0001). PD-L1 expression was similar with low level (1-49% TPS) ranging from 19% to 23% in the 2 groups. As anticipated, GA in genes associated with HRD including BRCA1 (6.6% vs 0.8%; P<0.0001), BRCA2 (25.0% vs 1.3%; P<0.0001), PALB2 (8.7% vs 0.3%; P<0.0001), and ATM (6.3% vs 3.4%; P=0.033) were all more frequent in the HRDsig+ iCCA. In contrast, GA in genes associated with iCCA targeted therapies were less frequent in the HRDsig+ cases including FGFR2 (8.0% vs 12.5%; P=0.033), IDH1 (3.5% vs 14.0%; P<0.0001) and ERBB2 (3.5% vs 5.7%; NS). In the HRDsig- group, 83.3%/74.1% of BRCA1 / BRCA2 mutated iCCA were mono-allelic likely non-driver GA respectively. MTOR pathway activating GA were more frequent in the HRDsig+ cases including PTEN (7.3% vs 3.3%; P=0.003) and NF1 (8.0% vs 2.8%; P<0.0001). MTAP deletion, an emerging iCCA target, was more frequent in the HRDsig+ iCCA (23.3% vs 16.9%; P=0.024). Conclusions: Nearly 5% of advanced iCCA feature HRDsig positive status which is associated with both significant differences in the frequencies of therapy associated genomic targets and the potential for introducing PARP inhibitors for these patients. HRDsig- iCCAN = 5983 HRDsig+ iCCAN = 288 P-value ATM 3.4% 6.3% 0.033 BRCA1 0.8% (83.3% mono-allelic) 6.6% <.0001 BRCA2 1.3% (74.1% mono-allelic) 25.0% <.0001 PALB2 0.3% 8.7% <.0001

Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.

Journal of Clinical Oncology Chengixn Liu, Wei Huang, Chengrui Fu et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.410

410 Background: Neoadjuvant chemotherapy or chemoradiotherapy followed by surgery is the standard of care for resectable locally advanced ESCC. SHR-1701, a new bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II, may enhance antitumor activity in combination with neoadjuvant standard therapies in ESCC patients (pts). The aim of this phase II trial is to determine the safety and efficacy of neoadjuvant chemoradiotherapy plus SHR-1701 followed by esophagectomy in pts with locally advanced resectable ESCC. Methods: Pts with resectable thoracic ESCC, diagnosed as clinical stage of cT1b-cT2N+M0 or cT3-cT4aNxM0 per AJCC 8th were eligible. Preoperative therapy included SHR-1701 (30 mg/kg every 3 weeks for 2 cycles), albumin paclitaxel (50 mg/m 2 , once a week for 5 weeks), carboplatin (AUC=2, once a week for 5 weeks) and radiotherapy (41.4Gy in 23 fractions). Following esophagectomy, pts received SHR-1701 up to 1 year. The primary endpoint was pathological complete response (pCR) rate in the per-protocol population. Secondary endpoints included R0 resection rate, major pathological response (MPR) rate, disease free survival (DFS) and safety. Results: Between Dec. 2021 and Feb. 2023, 43 pts were screened and 41 met the inclusion criteria, among whom the clinical stage I, II, III, and IVa at baseline were 1 (2.4%), 8 (19.5%), 31 (75.6%), and 1 (2.4%), respectively. All 41 pts received neoadjuvant SHR-1701 combined with chemoradiotherapy. As of Mar. 2024, 30 pts underwent surgery, and all achieved R0 resection. There was no in-hospital and postoperative 30-day mortality. 9 (30.0%) pts achieved pCR in both primary tumor and lymph nodes (ypT0N0), and 12 (40.0%) pts had complete pathological response of the primary tumor with residual disease in lymph nodes alone (ypT0N+). Treatment-related adverse events (TRAEs) occurred in all pts, and most of TRAEs were grade 1-2. Notable toxicity included pneumonitis (31.7%) and anastomotic leak (12.2%). Conclusions: The addition of SHR-1701 to neoadjuvant chemoradiotherapy in ESCC demonstrated promising efficacy with acceptable toxicity, and might be a promising approach for neoadjuvant treatment. Clinical trial information: ChiCTR2000041562.

Association between Healthy Eating Index-2020, alternative Mediterranean Diet scores, and gastrointestinal cancer risk in NHANES 2005–2018

Scientific Reports Weijie Wang, Yu Chang, Geng Chen Feb 01, 2025 DOI: 10.1038/s41598-025-88317-5

Phase II study of organ preservation (OP) in node-negative (NN) low rectal cancer (RC): Updated clinical and patient reported outcomes (PROs).

Journal of Clinical Oncology Vanessa Wookey, Jeffrey M. Farma, Joshua E. Meyer et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.148

148 Background: Total mesorectal excision (TME) is a highly effective treatment for rectal cancer (RC) but is associated with significant morbidity and mortality. Organ preservation (OP) approaches for locally advanced RC have been successful but not well studied for node-negative (NN) low RC. The objective of this investigator-initiated trial (IIT) is to determine the feasibility of performing successful local excision (LE) after neoadjuvant chemotherapy (CTX) in NN low RC. Methods: With IRB approval, patients (pts) with clinical stage T1-3, N0 low rectal adenocarcinomas (<6 cm from anal verge) were included in this single arm phase II IIT. Pts received 6 cycles of FOLFOX (5-FU bolus 400 mg/m2 and infusion 2400 mg/m2, Leucovorin 400 mg/m2, Oxaliplatin 85 mg/m2). Those with evidence of a response underwent LE (transanal excision) 6-12 weeks later. To target occult nodal metastases and reduce in-bowel recurrences, LE was followed by chemoradiotherapy ([CXRT] capecitabine 825 mg/m2 and long course RT to 54 Gy). The primary endpoint was the proportion of pts with successful LE after neoadjuvant CTX (NCT03548961). Results: Nineteen pts with low RC were enrolled; nine were female, and the mean age at diagnosis was 65 years. T stage was as follows: T1- 1(5%), T2 - 11(58%), T3 - 7(36%). Eighteen (95%) pts completed at least 5 cycles of neoadjuvant Ctx and 16/19 (84%) underwent LE. Negative margins were achieved in 79% (15/19), meeting our primary endpoint (p < 0.001). Ten (53%) were downstaged, and complete pathological response was achieved in 5/16 (31%) of pts who underwent LE. Four (21%) pts (all T2 stage) did not meet the primary endpoint (3 with inadequate response to CTX and 1 with LE and positive margins). Of these, three were salvaged (2 with CXRT; 1 with TME), and one died of infection (unrelated complication). All 16 who underwent LE completed CXRT. Of the 15 pts with successful OP at a median follow-up of 25.5 months, no local recurrences have been reported and 1 pt with lung nodules below the threshold for metastases at study entry ultimately developed clear lung metastases. Median DFS was not reached. Patient reported outcomes (PRO) assessment revealed a slight decline in physical health scores after neoadjuvant CTX but improved to baseline at follow-up. No decline was seen in mental health scores. Symptom specific QOL (sexual and bowel function) and long-term survival data will be presented. Conclusions: Neoadjuvant CTX and LE allows for OP in NN low RC and results in a margin negative LE in over three fourths of pts with durable long term local control and preserved QOL. Ongoing trials are investigating an OP approach in NN RC (NCT03259035). Our approach adds to the mounting evidence and will provide early data of the benefit of adjuvant chemoradiation to target occult nodes in this setting. Clinical trial information: NCT03548961 .

Influence of time to first therapy (TTFT) variable on survival outcomes of neoadjuvant chemotherapy versus upfront surgery approach in resectable pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology Qusai AlMasad, Aryanna Sousa, Paola Pena et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.720

720 Background: Evidence demonstrating overall survival (OS) benefit of neoadjuvant chemotherapy (NAC) followed by surgical resection over upfront surgical resection for resectable pancreatic ductal adenocarcinoma (PDAC) has been mixed. The time to first therapy (TTFT) variable has not been studied as a contributing factor. Methods: A nationwide retrospective analysis using the National Cancer Database to evaluate patients with clinical stage T1 and T2 PDACs from 2010 to 2020. Cox proportional hazards model was used to evaluate the impact of NAC followed by definitive surgery compared to upfront surgery on OS with and without TTFT. Results: Total of 43,196 patients were included – 9,880 patients with clinical stage T1 and 33,316 patients with T2 PDACs. There were increasing trends in the NAC approach from 2.9% in 2010 to over 25% by 2020 and decreasing trends in the upfront surgery approach from 69.35% in 2010 to 31.84% by 2020. There were significant differences in TTFT according to the treatment choice with upfront surgery group having a significantly shorter TTFT – proportion of those receiving first treatment within the 1 st week was 24.32% in the upfront surgery compared to 4.22% in the NAC group. In the adjusted cox regression without the TTFT variable, there was a 25% higher rate of death in the upfront surgery compared to the NAC group (HR 1.25, 95% CI 1.19 – 1.30). When the adjusted regression was performed with addition of a TTFT interaction term, there was survival disadvantage of upfront surgery approach in patients whose TTFT occurred after 1 week, but not in those with TTFT occurring in less than 1 week (HR 1.01, 95% CI 0.86 - 1.17). Conclusions: Our study emphasizes the importance of incorporating TTFT variable when comparing NAC versus upfront surgery approach in PDAC. Future studies comparing NAC to upfront surgery in resectable PDAC should consider incorporating the TTFT variable.

Patient-reported outcomes in physical, cognitive, and sexual health in early-onset gastrointestinal cancers (EOGIC).

Journal of Clinical Oncology Susan Feldt, Jenna Nimer, Afnan Shaik et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.72

72 Background: Incidence of early-onset (ages 18-49) gastrointestinal cancers is alarmingly increasing. To assess unmet needs in health-related quality of life (HRQoL), we conducted this pilot study using PRO measures in patients with EOGIC. Methods: Patients ages 18-49 with any GI cancer seen at our center during a clinic visit were invited to participate in this cross-sectional study. Validated PRO tools PROMIS 29+2, GP5 from FACT-G, AYA Sexual Health PRO Battery and Adult Neuro-QOL Cognitive Function short form were administered. Participants’ PROMIS 29+2 responses were scored to generate a T score, and two-tailed t-tests were used to compare T scores with the average score from a large general US population. The electronic medical record was reviewed to collect demographic, diagnosis and treatment information. Results: 39 (85% response rate) patients were enrolled from 03-08/24. Table 1 describes demographics, diagnoses, and treatment. In the PROMIS 29+2, EOGIC patients reported significantly lower physical function and higher anxiety, depression, fatigue and pain interference compared to the general US population: t-score (T-test p-value) 40.4 (p 0.0003), 57.7 (p 0.005), 55.7 (p 0.017), 55.1 (p 0.033) and 58.5 (p 0.0001), respectively. 56% reported being at least somewhat “bothered by side effects of treatment,” and this measure has a known correlation with clinician reported adverse events. Regarding sexual health (SH) in prior 30 days, 79% of participants felt less whole or “damaged” due to their disease, 64% were sexually active, 56% had some distress due to change in SH, and 50% were worried about their romantic relationship(s). Patients identified discussing safe sex with low counts, body image, contraception and addressing sexual problems as areas of unmet need during their care. They reported not receiving counseling from their care teams: only 15% discussed safe sex with low counts, 28% contraception, 13% STI prevention, and 18% discussed effect of cancer on body image. No significant change in cognitive functioning over the preceding 7 days was reported in this study. Conclusions: PROs are an important tool in clinical and survivorship care of young patients with GI cancers. We discovered that decreased physical function, increased anxiety, depression, fatigue and pain significantly effect HRQoL patients with EOGIC. We also found high unmet need to address sexual health in patients with EOGIC. Our ongoing work aims to better understand and address these needs for our patients. Demographic, diagnostic, and therapeutic characteristics of participants. Age At study participation 24-49 median 43 Gender Female 26 66.7% Primary cancer Colorectal 19 48.7% Pancreatic 5 12.8% Biliary tract cancers 5 12.8% Esophageal/Gastric 3 7.7% Other (including anal, NET, GIST, appendiceal) 7 17.9% Stage Metastatic 22 56.4% Treatment On any active treatment 24 61.5% On chemotherapy 20 51.2%

On QSPR analysis of pulmonary cancer drugs using python-driven topological modeling

Scientific Reports Huiling Qin, Mazhar Hussain, Muhammad Farhan Hanif et al. Feb 01, 2025 DOI: 10.1038/s41598-025-88419-0

Comparison of screening outcomes associated with advanced precancerous lesion versus colorectal cancer sensitivity for a blood-based test: A simulation study.

Journal of Clinical Oncology Vahab Vahdat, John B. Kisiel, Derek W. Ebner et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.89

89 Background: With estimates of over 150,000 incident and 50,000 fatal colorectal cancer (CRC) cases in 2024, efforts are ongoing to improve the national screening performance and engagement in the US. The Centers for Medicare & Medicaid Services (CMS) have established criteria for covering new blood-based CRC screening tests if minimum CRC sensitivity and specificity thresholds are met. However, the current blood-based tests are challenged by their relative inability to detect advanced precancerous lesions (APLs). At present, the importance of APL versus CRC sensitivity on screening outcomes remains undetermined. To address this knowledge gap, we conducted a simulation study to compare the screening effectiveness and outcomes of a hypothetical blood-based test across a range of sensitivities for CRC and APL detection. Methods: Outcomes were simulated using the CRC-AIM microsimulation model, which has been previously calibrated and validated. Predicted outcomes were calculated for average-risk individuals screened triennially with a blood-based test between ages 45-75 years, assuming perfect adherence. Base-case screening sensitivity and specificity inputs were based on CMS minimum thresholds (74% CRC sensitivity, 90% specificity) with assumed 10% APL sensitivity. Additional scenarios considered an increase in either APL or CRC sensitivity. Outcomes of interest included life years-gained (LYG), CRC incidence, and mortality reductions. Results: Compared to the CMS minimum performance (Table), increasing APL sensitivity by 1% (from 10% to 11%) resulted in a similar increase in LYG as compared to increasing CRC sensitivity by 11% (from 74% to 85%). Additionally, increasing APL sensitivity by 1% resulted in greater reductions in CRC cases and deaths (3% decrease) as compared to increasing CRC sensitivity by 11% (0% and 1% reductions, respectively). Conclusions: Data from this study show that increased APL sensitivity is a key determinant of screening-related outcomes, such as LYG, derived from a blood-based strategy, and that similar results would require much larger increases in CRC sensitivity. With the current CMS minimum performance threshold, blood-based tests that are designed to have high APL sensitivity can outperform tests with higher CRC sensitivity and little to no APL sensitivity. Comparison of CRC screening health outcomes with CMS proposed minimum threshold blood-test versus hypothetical tests with either increased APL and CRC sensitivity. APL Sensitivity CRC Sensitivity CRC Specificity Follow-up Colonoscopies CRC Cases (% reduction) CRC Deaths (% reduction) Life-Years Gained (LYG) (% increase) 10% 74% 90% 809 50 (ref) 18 (ref) 220 (ref) 11% 74% 90% 813 48 (-3%) 17 (-3%) 226 (3%) 10% 85% 90% 809 50 (0%) 18 (-1%) 227 (3%) APL: Advanced precancerous lesions; CRC: Colorectal cancer.

Development and validation of a prognostic model for advanced gastric and oesophageal carcinoma (AGOC) using individual patient data from two clinical trials.

Journal of Clinical Oncology Sayeda Kamrun Naher, David Espinoza, Peter S. Grimison et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.499

499 Background: Estimating survival in advanced gastric and oesophageal carcinoma (AGOC) remains a significant challenge. We developed a prognostic model incorporating readily accessible patient and clinical data and specific patient-reported outcomes (PROs), utilizing individual participant data from two randomized trials. Methods: We used data from 2 trials comparing regorafenib to placebo; AGITG INTEGRATE IIa (n=251) for model development and AGITG INTEGRATE (n=152) for validation. Both trials enrolled metastatic or AGOC following failure of 1 or more prior lines of systemic therapy. Candidate variables were chosen from systematic literature review and expert consultation. Significant prognostic factors for inclusion in the multivariable model were identified using univariable Cox proportional hazards models with p-value threshold of 0.1. Multivariable models were developed via Lasso regression. An initial model was created using clinical variables alone, followed by the integration of PROs. C statistics were used to discriminate the model’s efficiency. Results: Univariable analysis identified 9 clinical variables and 4 PRO domains as significant, including body mass index (BMI)(p=0.08), ECOG PS (0.02), extent of cancer (p<0.001), liver involvement (p=0.04), treatment with regorafenib (p=0.005), neutrophil-lymphocyte ratio (NLR) (p<0.001), LDH (p<0.001), albumin (p<0.001), and CA 19-9 (p=0.007). Significant baseline PROs included appetite loss (p<0.001), constipation (p<0.001), fatigue (p<0.001), and pain (p<0.001). Gastrectomy violated the Cox model proportional hazards assumption necessitating that the analysis be stratification by gastrectomy. The primary model (M1) incorporated region (Asia vs non-Asia, p=0.25, was included because it was significant in previous analysis (INTEGRATE), ECOG PS status, cancer extent, treatment with regorafenib, NLR, BMI, LDH, CA 19-9, and albumin. The final model (M2), which included PROs, demonstrated superior discriminative ability with the highest c-statistic values in both the gastrectomy and non-gastrectomy strata. The c-statistic increased from 0.695 for M1 to 0.723 for M2, indicating the added prognostic value of including PROs. Conclusions: The prognostic model that integrated both clinical data and PROs, proved robust for predicting survival in AGOC. The addition of PROs significantly enhanced prognostic accuracy, highlighting their importance in survival models. Further validation and refinement of the model is ongoing.

Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

Journal of Clinical Oncology Xiangrui Meng, Zhengzheng Shan, Lulu Guan et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.423

423 Background: The efficacy of first-line treatment in advanced GC/GEJC patients (pts) with negative or low PD-L1 expression still needs to be improved. This phase Ib/II, open-label study (NCT05024812) evaluating fruquintinib (a highly selective VEGFR-1, -2, -3 inhibitor) plus toripalimab (anti-PD-1), and SOX has shown preliminary antitumor activity as first-line therapy in GC/GEJC. Here we update the results with longer follow-up duration and a specific focus on PD-L1 CPS features. Methods: The study of phase Ib employed a 3+3 dose escalation design, pts were treated with fruquintinib 3mg/d (dose level; DL1), 4mg/d (DL2), or 5mg/d (DL3) po, d1-14, in combination with fixed dose of toripalimab (240mg, iv, d1), oxaliplatin (130 mg/m 2 , iv, d1) and S-1 (40-60mg based on BSA, po, d1-14) every 3 weeks. It had been reported in phase Ib that fruquintinib 5mg/d was defined as the RP2D. In phase II, a further 64 pts would be treated with the same regimen. Primary endpoint of phase II was PFS per RECIST 1.1. Secondary endpoints included ORR, DCR, OS, DOR and safety. Results: As of August 15, 2024, 32 pts (9 in phase Ib; 23 in phase II) had been enrolled. Pts characteristics included: median age 62 (range 38–73); 66% male; 88% with ECOG PS 1, and 31% with liver metastasis. 31 pts had PD-L1 CPS available. 40.6% were CPS < 1 and 68.8% were CPS < 5. Of the 30 pts evaluable for tumor response, the ORR was 63.5% (95% CI 43.9–80.1) with 4 pts achieving complete responses and DCR was 96.7% (95% CI 82.8–99.9). After a median follow-up of 10.94 months, the median PFS was 9.33 (95% CI: 5.68–NA) months and OS result was not reached. Pts with CPS < 5 were more likely to achieve higher response rate (65.0 vs 55.6%) and longer PFS than CPS ≥5 (12.68 vs 8.11 months). Similar trends were observed in pts with CPS < 1 and CPS ≥1 (ORR: 75.0 vs 52.9%; PFS: 12.68 vs 8.11 months). Treatment-related adverse events (TRAEs) were mainly grade 1-2 and the most common ones were hypoalbuminemia (50%), neutrophil count decreased (34%), anemia (41%), platelet count decreased (34%) and white blood cell decreased (34%). Grade 4 TRAEs occurred in 2 pts (impaired liver function, hypertriglyceridemia). There were no treatment related deaths in the trial. Conclusions: Fruquintinib combined with SOX and toripalimab provided favorable efficacy and manageable toxicity profile as first-line therapy for pts with advanced metastatic GC/GEJC, especially in pts with negative or low PD-L1 expression. More data including the potential predictive response biomarkers would be further analyzed and reported. Clinical trial information: NCT05024812 .

Habitat conservation enhances the resilience of the lizard Liolaemus cuyumhue to high summer temperatures

Scientific Reports María Victoria Brizio, Facundo Cabezas-Cartes, Luciano Javier Avila et al. Feb 01, 2025 DOI: 10.1038/s41598-024-83845-y